Dalpiciclib for HR+/HER2- advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called Dalpiciclib for people with a certain type of advanced breast cancer (HR-positive, HER2-negative). It aims to see if it can help stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced breast cancer that has spread or cannot be removed by surgery.
- Your cancer is hormone receptor-positive and HER2-negative.
- You are able to do your daily activities with little to no help (ECOG 0-1).
- You are not pregnant or breastfeeding.
- You do not have a history of a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy pill (dalpiciclib) combined with hormone therapy for women with advanced breast cancer that is hormone-receptor positive and HER2-negative. It may help shrink tumors or slow their growth when chemotherapy is not an option.
This trial tests whether adding the drug dalpiciclib to standard hormone therapy improves outcomes for people with a certain type of early breast cancer (hormone receptor-positive, HER2-negative). It may help lower the risk of the cancer coming back.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
This trial tests a new combination of two drugs (dalpiciclib and letrozole) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It aims to find the best dose to slow or stop cancer growth.
This trial is testing a new combination of medicines — a CDK4/6 inhibitor (dalpiciclib) plus hormone therapy and a blood pressure drug (olmesartan) — as a first treatment for advanced hormone-positive breast cancer. The goal is to see if this combination helps slow or shrink the cancer better than standard care.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.